US Edition
Published • loading... • Updated
Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxici
Pre-treatment improved circulation and cut liver uptake in mice, while reducing cGAS-STING inflammation in a preclinical study, the company said.
Summary by Benzinga
6 Articles
6 Articles
Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology
Preclinical evaluation in mice assessed the potential of the Nanobiotix Nanoprimer to overcome common barriers faced
Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxici
Preclinical evaluation in mice assessed the potential of the Nanobiotix Nanoprimer to overcome common barriers faced by lipid nanoparticle("LNP")-delivered therapies related to rapid liver clearance Pre-treatment with Nanoprimer followed by administration of LNP-delivered recombinant DNA ("LNP-DNA") designed for anti-tumor immunotherapy showed increased systemic bioavailability, reduced hepatic toxicity, and reduced cGAS-STING related inflammati…
·New York, United States
Read Full ArticleCoverage Details
Total News Sources6
Leaning Left0Leaning Right1Center3Last UpdatedBias Distribution75% Center
Bias Distribution
- 75% of the sources are Center
75% Center
C 75%
R 25%
Factuality
To view factuality data please Upgrade to Premium
